In Vivo Kidney Allograft Endothelial Specific Scavengers for On‐Site Inflammation Reduction under Antibody‐Mediated Rejection

Chang Liu, Pengpeng Yan, Xiaoyu Xu, Wenhui Zhou, Dhayakumar Rajan Prakash, ShuQi Wang, Rending Wang, Hongfeng Huang, Jianghua Chen, Hongbo Zhang*, Jia Shen

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

3 Citations (Scopus)
43 Downloads (Pure)

Abstract

Kidney transplantation is the most effective therapy for patients with end-stage renal disease. However, antibody-mediated rejection (ABMR) threatens long-term survival of renal grafts. Although ABMR can be controlled by donor-specific antibody clearance and B- or (and) plasma-cells inhibition, the treatment often causes severe side effects in patients. Therefore, there is need to explore site-specific scavengers. In this study, a nanovehicle carrying an anti-inflammatory drug is developed with complement component 4d targeting, a specific biomarker expressed on allograft endothelium under ABMR. Moreover, the nanovehicle is endowed with photothermal properties to control drug release. Analysis through systematic in vitro and in vivo toxicity, non-invasive targeted imaging, and in situ remote controlled drug release show the nanovehicle specifically targets allograft kidney endothelium, releases an anti-inflammatory drug, methylprednisolone, locally upon laser irradiation, and promotes recovery of injured endothelium, without affecting systemic inflammation or innate immune responses. This strategy has the potential for future clinical application in ABMR treatment.

Original languageEnglish
Article number2106746
JournalSmall
Volume18
Issue number36
DOIs
Publication statusPublished - 8 Sept 2022
MoE publication typeA1 Journal article-refereed

Fingerprint

Dive into the research topics of 'In Vivo Kidney Allograft Endothelial Specific Scavengers for On‐Site Inflammation Reduction under Antibody‐Mediated Rejection'. Together they form a unique fingerprint.

Cite this